DUBLIN--(BUSINESS WIRE)--The "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted BPDCN symptoms market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Blastic plasmacytoid dendritic cell neoplasm (BPDCN) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare entity grouped with the acute myeloid leukemia-related precursor neoplasms in the 2008 World Health Organization classification. It is a clinically aggressive tumor that often initially presents as cutaneous lesions and subsequently progresses to bone marrow involvement and leukemic dissemination characterized by enhanced expression of CD56, CD4, and CD123.
Patients with BPDCN have diverse clinical features, with cutaneous tumors in nearly all cases; the high incidence of such tumors distinguishes this disease from other myeloid cancers. Other sites of involvement include bone marrow, peripheral blood, lymph nodes, spleen, and other extramedullary organs. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with such diseases and skin lesions should be evaluated for BPDCN specifically.
BPDCN can be referred by different names such as blastic NK cell lymphoma, agranular CD4+ NK cell leukemia, blastic NK leukemia/lymphoma, and agranular CD4+ CD56+ hematodermic neoplasm. Also, as per WHO 2016 classification, BPDCN is currently classified as a distinct entity within the myeloid neoplasm and acute leukemia classification.
Scope of the Report
- The report covers the descriptive overview of BPDCN, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
- Comprehensive insight has been provided into the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
Report Highlights
- In the coming years, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Blastic plasmacytoid dendritic cell neoplasm (BPDCN) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for BPDCN. Launch of emerging therapies will significantly impact the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
- To understand the future market competition in the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
-
To understand the future market competition in the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market
Key Topics Covered:
1. Key Insights
2. Executive summary
3. Organizations
4. Epidemiology and Market Methodology
5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Market Overview at a Glance
5.1. Total Market Share (%) Distribution of BPDCN in 2017
5.2. Total Market Share (%) Distribution of BPDCN in 2030
6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Disease Overview
6.1. Introduction
6.2. Classification
6.3. Clinical Presentation
6.4. Pathogenesis
6.5. Diagnosis
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM
7.3. United States
7.4. EU5 Countries
7.5. Assumptions and Rationale
7.6. Germany
7.7. France
7.8. Italy
7.9. Spain
7.10. UK
7.11. Japan
8. Current Treatment Practices
8.1. Treatment Algorithm
9. Unmet Needs
10. Marketed drugs
11. Elzonris: Stemline Therapeutics
11.1. Drug Description
11.2. Regulatory Milestones
11.3. Other Development Activities
11.4. Clinical Development
11.5. Safety and Efficacy
11.6. Product Profile
12. Emerging Therapies
13. Key Cross Competition
14. MB-102: Mustang Bio
14.1. Product Description
14.2. Other Developmental Activities
14.3. Clinical Development
14.4. Safety and Efficacy
14.5. Product Profile
15. IMGN632: ImmunoGen/ Jazz Pharmaceuticals
15.1. Drug Description
15.2. Clinical Development
15.3. Safety and Efficacy
15.4. Product Profile
16. UniCAR02-T-CD123: Cellex Patient Treatment GmbH
17. Venetoclax: AbbVie
18. XmAb14045: Xencor
19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 7 Major Market Analysis
19.1. Key Findings
19.2. Market Size of Blastic plasmacytoid dendritic cell neoplasm in 7MM
20. Seven Major Market Outlook
20.1. United States Market Size
20.2. Germany
20.3. France
20.4. Italy
20.5. Spain
20.6. United Kingdom
20.7. Japan
21. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Japan
22. Total market size of Blastic plasmacytoid dendritic cell neoplasm by Line of Therapies in Japan
23. Market Drivers
24. Market Barriers
25. SWOT Analysis
26. Reimbursement policies
26.1. Current Therapies
27. Case Study
27.1. A Case Report of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
27.2. A Challenging Blastic Plasmacytoid Dendritic Cell Neoplasm Case
28. KOL Views
29. Appendix
30. Report Methodology
31. Capabilities
32. Disclaimer
33. About the Publisher
34. Bibliography
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/agh48q
